Autolus Therapeutics (NASDAQ:AUTL) Announces Quarterly Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) released its quarterly earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.06), Zacks reports.

Autolus Therapeutics Trading Down 11.7%

AUTL traded down $0.18 on Wednesday, hitting $1.33. 4,753,644 shares of the company’s stock traded hands, compared to its average volume of 2,359,644. The company’s 50 day simple moving average is $1.51 and its 200-day simple moving average is $1.81. Autolus Therapeutics has a one year low of $1.11 and a one year high of $3.54. The firm has a market cap of $352.64 million, a price-to-earnings ratio of -1.58 and a beta of 1.84.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on AUTL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Wells Fargo & Company decreased their target price on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, November 3rd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Autolus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $9.12.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Marex Group plc purchased a new position in shares of Autolus Therapeutics during the second quarter valued at about $28,000. Invesco Ltd. grew its holdings in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares in the last quarter. Jane Street Group LLC increased its stake in Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock worth $159,000 after acquiring an additional 91,222 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Autolus Therapeutics by 90.5% during the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock worth $375,000 after acquiring an additional 78,058 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.